<DOC>
	<DOC>NCT00553475</DOC>
	<brief_summary>To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in patients with painful diabetic peripheral neuropathy.</brief_summary>
	<brief_title>Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Visual Analogue Scale (VAS) of pain is higher than 40 mm. Diagnosis of type 1 or 2 diabetes mellitus for at least 1 year Malignancy within the past 2 years. Neurologic disorders unrelated to diabetic neuropathy that may confuse the assessment of neuropathy pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>